Home / Market News / $RDHL
benzinga Corporate Catalyst Impact 65/100 ● positive

RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively

Oct 19, 2026, 12:10 PM UTC · Primary ticker $RDHL

RedHill Biopharma's partner, the University of Oklahoma, received a $2.9 million NCI grant to study opaganib's effectiveness with CAR T-cell therapy in cancer patients. This funding enables two phases of clinical trials, potentially validating opaganib's role in enhancing cancer treatment and offering a new revenue stream for RedHill.

The University of Oklahoma, a partner of RedHill Biopharma, secured a significant $2.9 million grant from the National Cancer Institute. This funding is specifically allocated to conduct Phase 1b and Phase 2 clinical trials investigating RedHill's drug, opaganib, in conjunction with CAR T-cell therapy for cancer treatment. This development is a positive catalyst for RedHill as it provides external funding for clinical development of one of its key assets, reducing R&D costs and potentially validating opaganib's efficacy in a high-impact therapeutic area. For traders, this represents a long-term opportunity if the trials are successful, but short-term impact might be moderate as clinical trials are lengthy and outcomes uncertain. The key opportunity lies in the potential for opaganib to become a standard adjunct to CAR T-cell therapy, significantly expanding its market.

$RDHL positive Opaganib clinical trial funding and potential validation
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.